Since the introduction of oral contraceptives, their use has been associated with an
increased risk of both venous and arterial thrombosis. Pulmonary embolism, myocardial …

PIP: The discontinuation of oral contraceptive use at the time of diagnosis of systemic lupus
erythematosus (SLE) has been the usual practice in patients enrolled in the Hopkins Lupus …

Oral contraceptive (OC) use is associated with an increased risk of venous
thromboembolism. Previous data reported higher thrombotic risk in women using third …

The risk for venous thromboembolism (VTE) in medical patients is high, but risk assessment
is rarely performed because there is not yet a good method to identify candidates for …

Objective: To review the safety and tolerability of the contraceptive patch (Ortho
Evra™/Evra™) versus a standard oral contraceptive (Triphasil®) and to present the pooled …

With regard to oral contraceptives, much research has concentrated on venous thrombosis
and on the coronary and cerebral forms of atherosclerotic disease, while peripheral arterial …

Background Two recent studies, a cohort study from Denmark, and a case-control study from
The Netherlands, have reported increased risks of venous thromboembolism (VTE) among …

Adverse drug reactions (ADRs) represent an important risk for patients and have a
significant economic impact on health systems. ADRs are the fifth most common cause of …

Introduction The optimal management of oral contraception and menstrual bleeding during
treatment of venous thromboembolism (VTE) is largely unknown. We aimed to elicit expert …

Controversy exists regarding whether oral contraceptives (OCs) containing desogestrel and
gestodene are associated with an increased risk of venous thromboembolism (VTE) versus …